ArticleJAMA network open2025
External Validation of a Model for Predicting Outcomes in Preterm Newborns.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of a clinical scoring system for the prediction of methotrexate treatment response in rheumatoid arthritis patients: a multicenter real-world study.Therapeutic advances in musculoskeletal disease · 2026Article
- Error in Results Section.JAMA network open · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Predicting outcomes in preterm newborns is crucial for guiding therapeutic decisions and personalized rehabilitation. Prognostic models are a promising approach but rigorous validation is required to ensure their reliability and generalizability. Objective: To provide external validation of the PRETERM-POM model, a multimodal prognostic model developed for predicting outcomes in extremely preterm newborns at age 2 years. Design, Setting, and Participants: In this prognostic study conducted at Amiens-Picardie University Hospital (France), the original parameters of the model, developed through multivariate analysis and decision-tree algorithms, were applied to a temporal validation group of preterm newborns born between January 2018 and January 2021 that did not overlap with the development population. The study included preterm newborns born at 23 to 28 weeks of gestational age who had undergone cranial ultrasound and conventional electroencephalogram within the first 14 days after delivery and follow-up until a corrected age of 2 years. Main Outcomes and Measures: Neurodevelopment, assessed with the Denver Developmental Screening Test-II, was classified as favorable (no severe neurodevelopmental impairment [NDI]) or adverse (death or severe NDI). The area under the curve (AUC) for decision-tree classifications of adverse vs favorable outcomes was determined for the validation group and compared with the model development group using the DeLong test. Calibration and model fit were assessed using calibration-in-the-large, calibration curves, the Hosmer-Lemeshow test, and Brier score. Results: For the validation group (104 participants; median [IQR] gestational age at delivery, 26.3 [25.4-27.7] weeks; 46 [44.2%] male participants), the model achieved an AUC of 85.9% (95% CI, 79.0%-92.8%) for predicting outcomes, closely mirroring the performance observed in the development cohort. The model fit was good although it tended to underestimate the risk of adverse outcomes. Conclusions and Relevance: In this external validation study, the high performance of the model for predicting NDI in preterm newborns was confirmed. This multimodal approach, with a transparent display of risk factor contributions, enhances the potential of this model for clinical applications guiding timely management and decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.